WASHINGTON - The Food and Drug Administration cautioned patients Friday that using large amounts of a Johnson & Johnson foot ulcer drug could enhance their menaces of fading from cancer.

The FDA appended severe warning to the J& J foot ulcer cream with respect to Regranex which is approved to treat ruthless foot and leg ulcers in diabetics. The new boxed warning demonstrates that patients who used three or more tubes of Regranex over a 20-month period were five times more likely to be a victim of cancer.

FDA elucidated that the less amount of use of the cream could mitigate the chances of cancer. It is jut like those people who don’t use the drugs of J&J foot ulcer cream. This finding has come into observation through a long research and its analysis which showed that Reganex was used by a large amount of the people.

The latest brand name which is described in a black box warns doctors to use caution when prescribing the medicine to patients with tumors.

Regranex is a synthetic version of a core generated by the human body that assists cure ulcers. Since the medicine causes cells to split more quickly, the FDA claimed that Johnson & Johnson directly checked patients for reports of cancer, which increases through abandoned cell dissection. The FDA in March alleged it was evaluating the drug’s links to malignancy.

An orator for New Brunswick, N.J.-based Johnson and Johnson said that the company cooperated with FDA on the new brand and is “committed to getting the information out to physicians and patients.”

Almost 750,000 people had used the medicine since it was permitted by the FDA in 1997. The medicine is promoted by Ethicon Inc., an ancillary of Johnson & Johnson.
Shares of Johnson & Johnson have been decreased $1.20 to close at $65.76 Friday.

Related links

The Food and Drug Administration

FDA Adds On Cancer Caution

This article is the property of http://www.ElegantDirectory.com
Copying and publishing any article from our site is strictly NOT allowed